Similarly, abatacept-30mg showed significant superiority over the control group in ES at 20.5 months, belimumab at 23.3 months, and obinutuzumab at 22.6 months, with a decreasing trend.
← all excerpts
Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis.
1
—
—